Entera Bio Ltd
ENTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$141.46M
Close$
$0.14
94.9% downside
Current Fair Value
94.9% downsideOvervalued by 94.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $141.46 Million |
|---|---|
| Enterprise Value | $130.58 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.25 |
| Beta | 1.43 |
| Outstanding Shares | 50,451,232 |
Return
| Return on Equity | 219.52% |
|---|---|
| Return on Assets | 81.88% |
| Return on Invested Capital | -18.42% |
Valuation & Multiples
| P/E Ratio | -43.03 |
|---|---|
| PEG | 11.47 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -40.81 |
| Enterprise Value to Net Income | 8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 7, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 14, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 16.48%▼ 3.74% |
|---|---|
| Total Invested | $8.68M▼ 52.12% |
| Investors Holding | 26▲ 4.00% |
ESG Score
No data
About Entera Bio Ltd
17 employees
CEO: Adam Gridley Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challeng...